Kornimate/medical-research-clean huggingface dataset:
time from pci to cancer surgery and cardiovascular and oncologic outcomes

Conditions: Coronary Artery Disease; Cancer

Summary: to evaluate the association between time from pci to cancer surgery and cardiovascular and oncologic outcomes in early-stage cancer patients, a retrospective, population-based cohort study was conducted using data from the korean national health insurance service (k-nhis) database.

early-stage-cancer patients with a history of pci who underwent cancer surgery (n = 3621) were included. the patients were divided into two groups based on the time between the dates of pci and cancer surgery (\&lt;12 months and ≥12 months). patients were stratified into early-surgery and late-surgery, defined as patients who underwent surgery ≥1 and \&lt;1 month after cancer diagnosis. outcomes included bleeding, spontaneous myocardial infarction (mi), repeat revascularization, cancer recurrence, and death.

Eligibility criteria:
inclusion criteria: * men and women aged ≥18 years who were diagnosed with cancer and underwent cancer surgery within 1 year following diagnosis. * patients who underwent pci (procedure code: m6551-m6572, o1640-o1649, oa640-oa649) prior to the cancer surgery exclusion criteria: * participants who received neoadjuvant or adjuvant treatment for cancer

Keywords: time percutaneous coronary intervention cancer surgery
study of dietary composition in crohn's disease

Conditions: Inflammatory Bowel Diseases; Crohn Disease

Summary: patients with inflammatory bowel disease (ibd) often have narrowed microbial diversity and altered composition and function of the gut microbiome. we anticipate the anti-inflammatory diet, when compared with the usual diet, to produce favorable changes in these multi-omics profiles. these findings will provide insight into the interactions between diet and host biology, while providing clues on the mechanisms of diet therapy's effect and cd pathogenesis.

a randomized controlled trial of the anti-inflammatory whole food diet versus usual diet for the induction of remission in 104 adults with mild-to-moderate crohn's disease (cd). the anti-inflammatory whole food diet will be compared to participants usual diet for understanding its effects on achieving clinical remission, clinical response, reduction in serological and fecal markers of inflammation, and improvement in patient-reported outcomes, such as physical activity, anxiety, depression, fatigue, pain, sleep disturbance, social satisfaction, and quality of life. the study will involve collection of blood and fecal specimens to evaluate the effects of the anti-inflammatory diet on the gut microbiome, bacterial metabolome, innate immune markers, and fecal microrna profiles. the participants will be placed on anti-inflammatory diet for 8 weeks and assessed every 2 weeks for adherence.

Eligibility criteria:
inclusion criteria: * age of 18 to 75 years old * history of crohn's disease (cd) with mild to moderate symptoms and prior biopsy proof exclusion criteria: 1. history or current diagnosis of any of the following: * stroke or arrhythmia * seizures * liver disease * untreated hypertension (high blood pressure) * active malignancy * bleeding disorders * heart disease * lung disease * previous heart surgery * previous gastrointestinal surgery * kidney disease * chronic diarrhea * end enterostomy * bulimia * anorexia * laxative abuse * endocrine disorder * current history of smoking tobacco * urgent need for abdominal sugery * severe malnutrition * active alcohol or non-cannabinoid substance abuse 2. recent hospitalization within the last 30 days 3. currently pregnant of lactating. 4. current use probiotics or dietary supplements that would not be willing to discontinue for the length of the study. 5. concerns for non-compliance 6. if currently on immunosuppressants, immunomodulators, cotticosteroids, and/or 5-aminosalicylates, no changes in doses will be permitted during the trial except for tapering of corticosteroids.

Keywords: crohn's disease ibd anti-inflammatory diet
apelin in willis ekbom disease

Conditions: Restless Legs Syndrome

Summary: the purpose of this study is to assess apelin level in patients with willis-ekbom disease (wed) as known restless legs syndrome (rls). cardiovascular complications of wed have been reported in recent studies. increased oxidative stress is thought to play an important role in cardiovascular complications of wed patients. apelin is a novel described antioxidant bioactive peptide. the investigators hypothesize that patients with wed have lower plasma apelin level than healthy subjects based on presence of oxidative stress of wed.


Eligibility criteria:
inclusion criteria: * patients diagnosed as rls/wed according to international classification of sleep disorders (icsd-3) criteria * patients with idiopathic rls/wed * moderate and severe rls/wed according to international restless legs syndrome rating scale * periodic leg movements index above 5 in polysomnography record * bmi below 25 exclusion criteria: * disorders which cause symptomatic rls(iron deficiency anemia, kidney failure, diabetes mellitus, pregnancy, parkinson's disease, multiple sclerosis, neuropathy) * systemic diseases which cause possible oxidative stress status (cardiovascular diseases, obesity, diabetes mellitus, use of any medical drugs especially ace inhibitors e.g.) * another sleep disorder

Keywords: restless legs syndrome, apelin, oxidative stress
investigation of dysynchrony in patients with pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: the purpose of the study is to determine whether patients with pulmonary hypertension (ph) have dysynchrony, and if so whether it is electrical or mechanical. once this has been determined, during a catheterization the investigators will test if pacing the heart improves blood circulation.

this is a two part study of ventricular dysynchrony in patients with pulmonary hypertension. the first part is an observational study, reviewing routinely obtained clinical information (such as echocardiograms) to assess whether patients with pulmonary hypertension have electrical or mechanical dysynchrony. if so, we will proceed to the second part of the study which will assess whether temporarily pacing the right ventricle, during a clinically indicated catheterization can acutely improve hemodynamics. we will also gather control data for phase 1 from clinically indicated echos and ecg's in patients with asd's (rv volume load) and in patients who are evaluated for an innocent murmur ( nl heart). we hope to learn whether patients with pulmonary hypertension, and compromised right ventricles have electrical and mechanical dysnchrony. if this is true, it is theoretically possible that resynchronization (pacing) of the right ventricle could improve hemodynamics, symptoms and long term outcomes.

Eligibility criteria:
inclusion criteria: * pulmonary artery mean pressure at rest of 25 mm hg * controls (for phase 2) patients undergoing transcatheter closure of secundum asd patients undergoing echocardiogram and ecg as part of work-up for functional murmur who have normal intracardiac anatomy exclusion criteria: * reversible cause of pulmonary hypertension * age \< 5 yrs (for phase 2)

Keywords: mechanical dysynchrony electrical dysynchrony
lift-plug vs lift, a rct trial

Conditions: Anal Fistula; LIFT-plug; Healing Rate; Anal Function

Summary: to validate the effect of ligation of intersphincteric fistula tract (lift) versus lift-plug procedure for anal fistula repair in 7 medical centers

the management of trans-sphincteric anal fistulae of cryptoglandular origin is challenging. the ideal management is to effectively heal the fistula without compromising continence, avoid fistula recurrence, and quick recovery. ligation of the intersphincteric fistula tract (lift) and lift reinforced with a bioprosthetic graft (biolift) are two recently reported procedures that showed improved healing results. in the lift, rojanasakul et al proposed to identify the fistula tract in the intersphincteric space and subsequent division and ligation of the tract, and the primary healing rate was 94.4%. the following studies reported slightly lower results, but the recurrence rate was as high as 18% to 28%. ellis et al subsequently described a modified lift procedure (biolift procedure) in which a bioprosthetic was placed in the intersphincteric plane to reinforce the closure of the fistula tract (biolift procedure), and yielded a healing rate of 94% in 31 patients who had a minimum of 1 year of follow-up after their last treatment. the investigators modified the lift procedure by combining lift with the technique of anal fistula plug. the bioprosthetic plug was placed into the fistula tract through the opening in the external sphincter to the external opening in the skin after lift procedure. the present study was designed to assess the preliminary results of lift-plug technique prospectively. the purpose of this study is to validate the effect of ligation of intersphincteric fistula tract (lift) versus lift-plug procedure for anal fistula repair in 7 medical centers.

Eligibility criteria:
inclusion criteria: * high transsphincteric fistula (involving \> 30% of the external anal sphincter) * age between 18 and 70 years * chronic anal fistula with fistula tracts no more than 2 * no active sepsis or abscess exclusion criteria: * fistulas with active inflammation or purulence * fistulas related to tumor, crohn's disease, tuberculosis or acquired immune deficiency syndrome * poorly controlled diabetes with fasting blood-glucose \> 8mmol/l * preexisting incontinence * multiple fistula tracts \> 2 * fasting blood-glucose ≥ 8mmol/l * allergic or contraindication for the use of animal protein * pregnant women * expected life less than 6 months * with anorectal abscess * serious liver (child-pugh c) and chronic kidney disease (ckd) stage 3

Keywords: anorectal fistula lift-plug complications of treatment healing rate anal function
safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/velpatasvir in adults with chronic hcv infection who have not previously received treatment with direct-acting antiviral therapy

Conditions: Hepatitis C

Summary: the primary objectives of this study are to compare the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (sof/vel/vox) fixed dose combination (fdc) for 8 weeks with that of sof/vel fdc for 12 weeks in direct-acting antiviral-naive participants with chronic hepatitis c virus (hcv) infection.


Eligibility criteria:
key inclusion criteria: * willing and able to provide written informed consent * hcv rna ≥ 10\^4 iu/ml at screening * chronic hcv infection (≥ 6 months) * hcv treatment naive or treatment experienced with an interferon (ifn)-based regimen * use of protocol specified methods of contraception key exclusion criteria: * current or prior history of clinically significant illness that may interfere with participation in the study * screening ecg with clinically significant abnormalities * laboratory parameters outside the acceptable range at screening * pregnant or nursing female * chronic liver disease not caused by hcv * infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv) note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: chronic hepatitis c infection
the alberta bloom long term follow up study

Conditions: Infant, Premature, Diseases; Infant; Asthma; Asthma in Children; Allergies; Infant, Extremely Premature

Summary: this is a prospective, observational clinical cohort study involving children born very preterm at less than 31 weeks and six days gestation. the purpose of this study is to investigate the microbiome (the collection of microbes in a biological site) alternations resulting from preterm birth and associations with the risk of immune dysregulation, asthma and allergies.

one important factor in gut health is the large community of microbes (tiny living things such as bacteria) that live on the human body called the microbiome. recent studies have shown that premature babies are more likely to have changes in their gut microbiome that are associated with health issues. however, the specific microbiome features that are involved in the development of premature babies is still unknown. therefore, this study examines the impact of very premature birth on the baby's microbiome, and how microbiome alterations are involved in health issues such as immune dysregulation, allergies and asthma. the large communities of microbes in the gut play a major role on the microbiome that will form during infancy and childhood. factors such as diet, exposure to antibiotics, surgical procedures, and mode of delivery, can strongly affect the dynamics microbiome development. it is well known that microbiome alterations are associated with disorders such as asthma. however, the features involved in disease development and progression are highly understudied. through this clinical study, we will evaluate associations between the early patterns of microbial colonization in premature infants and their risk to develop asthma later in childhood. the hypothesis of the study is that microbial alterations resulting from preterm birth causally contribute to the allergy and asthma risk in infants (defined by atopic-wheeze) through immune mechanisms.

Eligibility criteria:
inclusion criteria: 1. born at ≤ 31 weeks + 6 days gestation (316/7 weeks); 2. previously participated in the probio and/or bloom ptn and/or bloom ptb research studies. 3. provide a signed and dated informed consent form. 4. willing and able to attend a clinic visit at alberta children's hospital in calgary, alberta. 5. parent/guardian providing consent must be able to speak and understand english. exclusion criteria: 1. has congenital gastrointestinal anomalies or has a history of gastrointestinal surgery. 2. has major chromosomal anomalies.

Keywords: microbiota microbiome gastrointestinal microbiome
ketamine prevent pocd

Conditions: Necrosis of Femoral Head; Knee Osteoarthritis

Summary: previous study demonstrated that neuroinflammation induced by surgery is the main cause of the postoperative cognitive dysfunction. as an agonist of nmda receptor, ketamine is proved to be an anti-inflammation agent. in present study investigators hypothesized that low dose ketamine would prevent the cognition decline after orthopedic surgery in aged patients.


Eligibility criteria:
inclusion criteria: * elder than 60 * easily communicated with chinese * selected to kneel or hip replacement * agree to take part into this clinical trail exclusion criteria: * existing cerebral disease， or have a history of neurological and psychiatric disease including ad, stroke and psychosis * existing cognitive impairment as evidenced by mini-mental state examination scores below 24 * several audition or vision disorder * preoperative systolic blood pressure over 190mmhg or diastolic pressure \>100mmhg * existing a history of hyperthyroidism * patient with glaucoma * unwillingness to comply with the protocol or procedures

Keywords: postoperative cognitive dysfunction ketamine surgery
evaluation of drug spread in ultrasound-guided erector spina plane block with fluoroscopy

Conditions: Pain, Myofacial; Back Pain

Summary: the purpose of this study is to evaluate the injectate spread in erector spinae plane blocks under fluoroscopy.

the study will be carried out between march 2021 and june 2021 in istanbul university istanbul medical faculty pain medicine clinic. patients who undergone erector spinae plane block for any indication over the age of 18 will be included in the study. all procedures will be performed in the operating room under standard monitorization (ecg, pulse oximetry, non-invasive blood pressure) and all patients will be in the prone position. the application area will be sterilized with povidone-iodine solution. mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. the target area will be visualized by general electrics (ge) logiq e ultrasound device using a 10-12 mhz linear probe or 1-4 mhz curvilinear probe. transverse processes and erector spina muscles will be visualised at the target vertebral level. after local anesthesia (1-2 cc 2% lidocaine), a 20 gauge spinal needle will be inserted using the "in-plane technique". the needle will be advanced to the transverse process, after it's position is confirmed with hydrodissection, a solution of 40 mg triamcinolone, 10 ml 0,5% bupivacaine, 10 ml radiopaque contrast agent will be injected. contrast spread will be evaluated with the fluoroscopy in the anterior-posterior and lateral positions immediately and 30 minutes after the procedure. the level of contrast radiating in the ap plane and passing through the paravertebral space and the epidural distance in the lateral plane will be noted. in addition, sensory examination with a pin prick test will be performed to determine the presence of dermatomal hypoalgesia and/or analgesia.

Eligibility criteria:
inclusion criteria: 1. age over 18 years old 2. patients who underwent erector spinae plane block for any reasons exclusion criteria: 1. age under the age of 18 2. patients without a clear contrast spread under fluoroscopy

Keywords: erector spinae plane block
the role of no-calorie beverages within a weight loss program

Conditions: Obesity

Summary: the no calorie drink study is looking for over 300 people to participate. the study is evaluating the effect of no calorie beverages on weight loss and weight maintained over time in people who drink diet beverages every day as compared to water only drinkers during the 1 year study period.

this investigation aims to test the hypothesis that the amount of weight lost and maintained over time in an intensive behavioral weight management program will be equivalent in subjects consuming beverages containing no calorie sweeteners as compared to water beverages.

Eligibility criteria:
inclusion criteria: * body mass index: 27 - 40 kg/m2 * must drink no calorie, sweetened drinks exclusion criteria * cardiovascular disease * uncontrolled blood pressure * smoker * medications that affecting metabolism * oral steroids * history of stroke or seizures * thyroid disease * type 1 or 2 diabetes * cushings syndrome * renal disease * liver disease * cancer in the past 5 years * hiv * active tuberculosis * major psychiatric disorders

Keywords: obesity, weight loss, weight maintenance
a 40-week study to evaluate tnx-102 sl 5.6 mg taken daily at bedtime in patients with ptsd

Conditions: PTSD

Summary: evaluate the long-term safety of tnx-102 sl 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with ptsd who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (tnx-cy-p303).

this is an open-label, extension trial designed to evaluate safety over 40 additional weeks of tnx-102 sl therapy taken daily at bedtime for the treatment of ptsd. the study will consist of 5 in-clinic study visits, including baseline visit 1 (day 0, which is anticipated to be the same visit as the last visit of the 12-week open-label extension study tnx-cy-p303), followed by in-clinic visits after 7, 16, 28 and 40 weeks of open-label treatment.

Eligibility criteria:
inclusion criteria: * the patient has completed a double-blind lead-in honor study and a 12-week open-label extension study p303 and is judged by the investigator as reasonably compliant, with at least 60% compliance with study medication usage (based on drug accountability). * the patient has provided written informed consent to participate in this extension study. * the patient met all prior inclusion and exclusion requirements for the double-blind lead-in honor study, or the site received medical monitor approval for the patient to remain in the lead-in study after the retrospective discovery of an entry violation that did not pose any threat to the patient's safety or well-being. * during the course of the lead-in honor study or 12-week open-label extension p303 study, the patient has had no intervening medical conditions including pregnancy, clinically significant increase in suicidal ideation (plan or intent) or significant worsening of depression, newly arising clinically significant abnormal laboratory tests, or any clinically significant, uncontrolled, or unstable medical or surgical condition that could affect the patient's ability to participate in the study or potentially compromise the patient's well-being during the study. * the patient does not require treatment with a potent (strong) cytochrome p450 subtype 3a4 (cyp3a4) inhibitor, or st. john's wort. * the patient is willing to refrain from use of all other formulations of cyclobenzaprine for the duration of the study. * the patient is willing to refrain from use of monoamine oxidase inhibitors for the duration of the study. * female patients of childbearing potential continue to agree to practice one of the medically acceptable methods of birth control detailed in the lead-in study. exclusion criteria: * there are no exclusion criteria for this study.

Keywords: tnx-102 sl bedtime sublingual safety ptsd
platelet-rich plasma injection for ulnar neuropathy at elbow

Conditions: Ulnar Neuropathy at Elbow

Summary: ulnar neuropathy at elbow (une) is the second common peripheral entrapment neuropathy after carpal tunnel syndrome (cts). although many conservative managements of une were found, their effectiveness were often unsatisfied without existed guideline. recently, the perineural injection of 5% dextrose wate (d5w) is a novel management for cts but its effect for une is not obviously as cts. hence, it is very important to find another novel injectate for une.

the platelet-rich plasma (prp) is a new and potential treatment for patients with kinds of musculoskeletal disorders and recent reports showed being beneficial for peripheral neuropathy in animal studies. our previous research shown single injection with prp was superior to d5w for cts. however there is no study investigating the effect of prp for une now. hence, the purpose of this study was to assess the effect of perineural prp injection for une.

Eligibility criteria:
inclusion criteria: 1. age between 20-80 year-old. 2. diagnosis as ulnar neuropathy at elbow at least one month exclusion criteria: 1. cancer 2. coagulopathy 3. pregnancy 3. any active infection status 4. polyneuropathy of upper extremity 5. brachial plexopathy 6. thrombocytopenia previously undergone wrist surgery or steroid injection for ulnar neuropathy

Keywords: ulnar neuropathy at elbow platelet-rich plasma perineural injection